应《网络安全法》要求，自2017年10月1日起，未进行实名认证将不得使用互联网跟帖服务。为保障您的帐号能够正常使用，请尽快对帐号进行手机号验证，感谢您的理解与支持！

24小时热门版块排行榜    

小木虫论坛-学术科研互动平台 » 学术交流区 » 论文投稿 » 论文写作 » 投稿第一篇SCI，7月份收到编辑部回信，请问修回后中的机会大不大啊
51/1返回列表
查看: 2757  |  回复: 15
只看楼主 @他人 存档 新回复提醒 (忽略) 收藏    在APP中查看
当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖

常八九无二三

新虫 (初入文坛)
已领完
投稿第一篇SCI，7月份收到编辑部回信，请问修回后中的机会大不大啊
领取红包 (小木虫手机app专属红包)

扫一扫，下载小木虫客户端

意见如下

Reviewers' comments:
------------------------------------------------------
Reviewer E:

The manuscript by Wu et al. reviews the role of Gli-associated oncogenes, in
particular Gli-1, in cancer development, and as a potential target for
cancer therapy.  Gli-1 is an important oncogene and is found to be
overexpressed in a variety of cancers.   The manuscript provides a good
overview of the current state of knowledge of the role of Gli-1 in mediating
signalling through the Hedgehog pathway, and how alterations in Gli-1 may
contribute to cancer development.  The manuscript also focuses on the
potential of inhibitors of Gli-1 and other components of the Hedgehog
pathway to be used in cancer therapy.  An extensive reference list is
provided, covering relevant articles in the field.

However, there are two major issues with the current manuscript which must
be corrected before it could be published.

1.        The grammar requires extensive correction, as the errors detract
significantly from the meaning of the key points, and would make it
difficult for readers to fully understand the points being made in the
review.  

2.        In particular in the discussion of inhibitors of Gli-1 and other
components of the Hedgehog pathway, a clear distinction must be made between
effects demonstrated in cell culture, models, in xenograft experiments in
animal models, and effects in clinical trials.  This distinction is not
clear in the present manuscript, and this will lead to confusion on the part
of readers as to the current state of development of Gli-1 inhibitors for
cancer treatment.   For example, resveratrol is described as a medicine
(Section 1.3), but this may be an overstatement.   A more critical analysis
of the data with regard to potential Gli inhibitors is required in order for
the review to be of maximum benefit to cancer researchers.

Reviewer L:


        The work titled “Glioma-associated oncogene especially Gli-1 function in
the carcinogenesis and cancer targeted therapy” is based on an interesting
area. The work can be considered for publication; however, it needs some
serious revisions before its acceptance. The manuscript must be revised as
per following comments-
1.        The title looks difficult to understand, it may be revised something like
Role of glioma-associated Gli-1 oncogene in the carcinogenesis and cancer
targeted therapy.
2.        Information provided in the manuscript is not adequate as I can see few
important researches like “Scientific Reports 6, Article number: 22184
(2016)”, BMC Cancer. 2009;9:298, etc. are not included.
3.        Language editing is also required as few phrases are written
grammatically wrong for example, “in abstract section - Glioma-associated
oncogene (Gli) belongs…”; “in introduction - therapeutic target for
cancers…; resveratrol and cyclopamine”; “GLI-1 CLOSLY RELATED”;
“Moreover,…”; “exerts anticancer effects through”; “ITRA, an
inhibitor of Smo”, etc.
4.        Delete phrase “In our review, we summarized the Gli function in the
carcinogenesis and cancer targeted therapy” from introduction section as
it is also written in the abstract.

------------------------------------------------------
Editorial comments:

This MS covers a good topic. However, there are major concerns over the
presentation and the language quality. The following should be carefully
addressed by the authors:

1.        The rationale and the significance should be clearly stated in the
introduction section.
2.        The abstract should be expanded to cover the major findings in the field.
3.        The references should be updated.
4.        A professional editing for language and style is needed. A certificate
for such an editing should be provided when resubmitting this MS.
5.        The CCDT format should be followed.
   

-----------------------------------------------------

发自小木虫Android客户端

[ Last edited by 常八九无二三 on 2017-8-27 at 14:56 ]
回复此楼

» 猜你喜欢

» 抢金币啦！回帖就可以得到:

查看全部散金贴
1楼 2017-08-27 14:40:21
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

虾米爱虫虫

新虫 (小有名气)
★
liouzhan654: 金币+1, 感谢交流 2017-08-27 15:07:57
让修改机会就大

发自小木虫IOS客户端
回复此楼
9楼2017-08-27 14:52:12
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
查看全部 16 个回答

瑟可米瑟

新虫 (正式写手)
挺大啊

发自小木虫Android客户端
回复此楼
10楼2017-08-27 14:56:17
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

小川哲梦

铁杆木虫 (著名写手)
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
好好修改，机会还是蛮大的，最怕就是连修改的机会都没有。

发自小木虫IOS客户端
赞一下(1人) 回复此楼
11楼2017-08-27 21:38:30
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

caolinzk789

禁虫 (正式写手)
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
本帖内容被屏蔽
14楼2017-09-02 01:43:47
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
简单回复
zzjj_2073楼
2017-08-27 14:40   回复  
常八九无二三(金币+1): 谢谢参与
已获得1个金币 发自小木虫IOS客户端
逝水无痕199012楼
2017-08-27 23:12   回复  
橘色翡冷翠2楼
2017-08-27 14:40   回复  
常八九无二三(金币+2): 谢谢参与
已获得2个金币 发自小木虫Android客户端
54061623613楼
2017-08-28 06:17   回复  
FQ11118楼
2017-08-27 14:40   回复  
常八九无二三(金币+2): 谢谢参与
已获得2个金币 发自小木虫Android客户端
oil-shale4楼
2017-08-27 14:40   回复  
常八九无二三(金币+1): 谢谢参与
已获得1个金币 发自小木虫Android客户端
常清泉6楼
2017-08-27 14:40   回复  
常八九无二三(金币+1): 谢谢参与
已获得1个金币 发自小木虫Android客户端
hlj格桑花7楼
2017-08-27 14:40   回复  
常八九无二三(金币+1): 谢谢参与
已获得1个金币 发自小木虫Android客户端
150294815325楼
2017-08-27 14:40   回复  
常八九无二三(金币+2): 谢谢参与
已获得2个金币 发自小木虫Android客户端
查看全部 16 个回答
普通表情 龙 兔 虎 猫 高级回复 (可上传附件)
最具人气热帖推荐 [查看全部] 作者 回/看 最后发表
[考博] 售一区SCI文章T0P，我:8O.551.O54,科目全,可十急 +3 6GojgJvkDudM 2026-08-16 4/200 2026-08-17 13:49 by EYK67XJMj64E
[基金申请] 欢迎发来filecode的Mz6后的代码验证其规律 +33 医学老男孩 2026-08-13 78/3900 2026-08-17 13:22 by ziyangfang
[基金申请] 哪位老哥知道今年的国自然具体哪一天放榜？ +12 Ldrop2023 2026-08-13 13/650 2026-08-17 12:33 by gltch
[教师之家] 售SCI一区T0P文章，我:8.O.55.1.O.5.4,科目全,可+急 +3 6GojgJvkDudM 2026-08-16 3/150 2026-08-17 09:49 by xLVPIRuSvCUe
[论文投稿] 岩土工程学报什么时候才能终审完呐 25+3 yeager111 2026-08-10 4/200 2026-08-16 20:42 by tfang
[基金申请] 时间戳又变了8-15 +13 archvillain 2026-08-15 25/1250 2026-08-16 20:13 by zhaosm1982
[基金申请] 2027广东省杰青 +3 奶牛小黑 2026-08-15 6/300 2026-08-16 20:07 by 奶牛小黑
[基金申请] 有时候，自然基金真的不能太认真 （我的申报经验） +10 majunge000 2026-08-11 12/600 2026-08-16 08:18 by xli1984
[精细化工] 招聘 金属平磨液，抛光液研发工程师 +3 小天0311 2026-08-14 3/150 2026-08-16 07:31 by H9PLUS
[基金申请] 各位道友，我要去昆明玩几天，回来见。 +7 Tide man 2026-08-14 8/400 2026-08-15 01:11 by arzu_hma
[基金申请] 是这周出结果还是下周出结果？ +4 yuleib84 2026-08-11 4/200 2026-08-14 23:05 by lfy8008
[硕博家园] 读博的好处 +4 lnee 2026-08-11 4/200 2026-08-14 10:20 by ahsoarli
[基金申请] filecode +15 documentary 2026-08-10 17/850 2026-08-14 10:08 by kissu88
[基金申请] 静等基金结果 +8 gjjjzhong 2026-08-10 21/1050 2026-08-13 17:56 by 且听虎啸
[基金申请] Filecode 又变了，巨变 +3 WH3796 2026-08-12 4/200 2026-08-13 14:13 by 小木虫6752397
[基金申请] 分享一下我之前已中青C的计划书的filecode +4 布布和一二 2026-08-11 5/250 2026-08-13 12:56 by cratir
[基金申请] 结合人工智能，周易传统文化，filecode打分制来了，3分以上希望很大。 +3 Tide man 2026-08-12 4/200 2026-08-13 08:35 by ZJTJZ
[基金申请] 帮忙看看fileCode +7 wwncly 2026-08-10 13/650 2026-08-11 19:36 by 冰心玉壶晴
[基金申请] 什么时候出结果，有咨询渠道？？？ +3 Tide man 2026-08-11 3/150 2026-08-11 17:54 by kudofaye
[基金申请] 确定了，国自然21号放榜 +6 布布和一二 2026-08-10 7/350 2026-08-10 19:15 by 2000zf36392
信息提示
关闭
请填处理意见
关闭